Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Jonsson Comprehensive Cancer Center
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
73High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07229339CT.gov Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT07234877CT.gov Phase II Study of Upfront SRT Plus Ivonescimab/Chemotherapy vs Ivonescimab/Chemotherapy in NSCLC Brain Mets | — | Not Yet Recruiting | — | — | — |
NCT07247786CT.gov Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT) | — | Not Yet Recruiting | — | — | — |
NCT07405190CT.gov Ivonescimab Alone And With Carboplatin/Pemetrexed For NSCLC | — | Not Yet Recruiting | — | — | — |
NCT07622186CT.gov A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC) | — | Not Yet Recruiting | — | — | — |
NCT07586202CT.gov A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC | — | Not Yet Recruiting | — | — | — |
NCT07603791CT.gov Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants. | — | Not Yet Recruiting | — | — | — |
NCT06694454CT.gov Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC) | — | Recruiting | — | — | — |
NCT07623356CT.gov A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Non-Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT07486817CT.gov Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab | — | Recruiting | — | — | — |
Show 768 more trialsShow fewer
NCT07633873CT.gov SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for Patients With PD-L1-Positive Locally Advanced or Metastatic NSCLC（SYNSTAR 04） | — | Not Yet Recruiting | — | — | — |
NCT07642024CT.gov A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09) | — | Not Yet Recruiting | — | — | — |
NCT07524257CT.gov Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC | — | Not Yet Recruiting | — | — | — |
NCT07279935CT.gov Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resectable SIB-IIIA NSCLC. | — | Recruiting | — | — | — |
NCT07365319CT.gov A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer. | — | Recruiting | — | — | — |
NCT07643350CT.gov Efficacy and Safety of Induction Benmelstobart Plus Anlotinib and Chemotherapy Followed by Concurrent Chemoradiotherapy and Benmelstobart Maintenance Versus Concurrent Chemoradiotherapy Followed by Benmelstobart Maintenance in Patients With Unresectable Stage III NSCLC | — | Not Yet Recruiting | — | — | — |
NCT07420439CT.gov Treatment in Patients With Advanced Non-Small Cell Lung Carcinoma and Interstitial Lung Disease | — | Not Yet Recruiting | — | — | — |
NCT07001995CT.gov Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression | — | Not Yet Recruiting | — | — | — |
NCT07554846CT.gov Comparison of Perioperative Immunotherapy, Adjuvant Immunotherapy or Neoadjuvant Immunotherapy for Resectable Stage II-IIIA NSCLC | — | Not Yet Recruiting | — | — | — |
NCT07538193CT.gov Iparomlimab and Tuvonralimab Plus Chemotherapy Before Surgery for Stage III Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT07020065CT.gov Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% | — | Recruiting | — | — | — |
NCT07507188CT.gov Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study) | — | Not Yet Recruiting | — | — | — |
NCT07416474CT.gov RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC) | — | Recruiting | — | — | — |
NCT07453394CT.gov QLS5132 Combination Therapy in Advanced Solid Tumors | — | Not Yet Recruiting | — | — | — |
NCT07354061CT.gov Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC) | — | Recruiting | — | — | — |
NCT07472478CT.gov Phase II Neoadjuvant Study of Garsorasib Followed by Ivonescimab Plus Chemotherapy in Resectable Stage IIA-IIIB KRAS G12C-Mutant NSCLC (GIVEN Study) | — | Not Yet Recruiting | — | — | — |
NCT07485179CT.gov Emulation of the KEYNOTE-042 (NCT02220894) Trial Using Specialty Oncology Electronic Health Records Databases | — | Active Not Recruiting | — | — | — |
NCT07336732CT.gov Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations | — | Recruiting | — | — | — |
NCT07493980CT.gov Study on the Efficacy and Safety of JSKN016 as Neoadjuvant Therapy in Resectable Stage II-III Non-small Cell Lung Cancer Patients | — | Not Yet Recruiting | — | — | — |
NCT07397338CT.gov Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors | — | Recruiting | — | — | — |
NCT07383116CT.gov Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT07410975CT.gov Efficacy of Anti-CTLA-4 Antibody Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-III Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT07063745CT.gov A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion | — | Recruiting | — | — | — |
NCT07274384CT.gov Hyperprogression in PD-L1 ≥ 50% NSCLC: a Biomarker Guided Phase 2 Trial | — | Not Yet Recruiting | — | — | — |
NCT07365410CT.gov Furmonertinib 160mg vs 80mg + Chemotherapy in EGFR-Mutated NSCLC With Brain Metastases: Efficacy and Safety Study | — | Not Yet Recruiting | — | — | — |
NCT07309952CT.gov Neoadjuvant SBRT Followed by Sintilimab Plus Chemotherapy for N3-Positive NSCLC | — | Recruiting | — | — | — |
NCT06405230CT.gov Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC) | — | Recruiting | — | — | — |
NCT07128199CT.gov A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection | — | Active Not Recruiting | — | — | — |
NCT07200947CT.gov A Phase II Study of QL1706 and Platinum-Based Chemotherapy in Patients With SMARCA4-Deficient, Locally Advanced or Metastatic Non-Small Cell Lung Cancer. | — | Not Yet Recruiting | — | — | — |
NCT07256509CT.gov A Study of SYS6010 Combined With Osimertinib Versus Osimertinib Alone as Neoadjuvant Therapy for Patients With EGFR Mutation-positive Resectable Non-squamous Non-small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06996782CT.gov A Platform Study in Non-Small Cell Lung Cancer (NSCLC) | — | Recruiting | — | — | — |
NCT07229729CT.gov A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT07001618CT.gov Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06656598CT.gov Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer | — | Recruiting | — | — | — |
NCT07100080CT.gov Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01) | — | Recruiting | — | — | — |
NCT07647094CT.gov A Prospective, Multicenter, Randomized Controlled Study on the Efficacy and Safety of Low-dose Carboplatin Combined With Nab-Paclitaxel and Delayed Administration of Serplulimab as First-line Treatment for Advanced Squamous Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT07171606CT.gov A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer（NSCLC） Patients | — | Recruiting | — | — | — |
NCT06793215CT.gov A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT07190248CT.gov A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007) | — | Recruiting | — | — | — |
NCT06822543CT.gov A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer) | — | Recruiting | — | — | — |
NCT07178795CT.gov A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC | — | Recruiting | — | — | — |
NCT07160335CT.gov A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors | — | Recruiting | — | — | — |
NCT07111520CT.gov A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC) | — | Recruiting | — | — | — |
NCT06946797CT.gov A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC) | — | Active Not Recruiting | — | — | — |
NCT07173244CT.gov A Real-world Study of Adebrelimab-based Combination Regimens in the Treatment of Advanced Solid Tumors | — | Not Yet Recruiting | — | — | — |
NCT07174908CT.gov A Phase 3 Study of IN10018 in Combination With D-1553 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation | — | Recruiting | — | — | — |
NCT07082179CT.gov A Prospective Phase II Clinical Study of Immunotherapy Combined With Chemotherapy for Stage III Unresectable Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT07181499CT.gov Sequential Chemotherapy With Befotertinib in Non-Small Cell Lung Cancer (NSCLC) Patients With Resistance to Third-Generation EGFR-TKI | — | Recruiting | — | — | — |
NCT06484491CT.gov IMPT Dose Escalation for NSCLC (HyDose) | — | Recruiting | — | — | — |
NCT07109531CT.gov ASKC202 Combined With Limertinib Versus Platinum-based Chemotherapy in Treatment of Locally Advanced or Metastatic NSCLC With MET Amplification/Overexpression After Failure of EGFR-TKI Therapy | — | Not Yet Recruiting | — | — | — |
NCT07122687CT.gov IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT07093762CT.gov Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC | — | Not Yet Recruiting | — | — | — |
NCT07063329CT.gov Phase I/II Study of PLB1004 Combined With Platinum-based Doublet Chemotherapy in Patients With EGFR Mutation-positive | — | Not Yet Recruiting | — | — | — |
NCT07005102CT.gov A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT07098988CT.gov Trial Investigating Visugromab in Combination With Immunochemotherapy in 1L Treatment of Participants With Metastatic NSCLC | — | Recruiting | — | — | — |
NCT06897046CT.gov Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC | — | Recruiting | — | — | — |
NCT06917573CT.gov PALACE: Cemiplimab Trial According to ctDNA Levels | — | Recruiting | — | — | — |
NCT07046923CT.gov A Study of LY4175408 in Participants With Advanced Cancer | — | Recruiting | — | — | — |
NCT07070440CT.gov DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7) | — | Recruiting | — | — | — |
NCT06953843CT.gov Study on the Optimal Combination Pattern of the Combined Treatment of Radiotherapy and Immunotherapy for the Abscopal Effect in Non-Small Cell Lung Cancer (NSCLC) With Multiple Metastases | — | Recruiting | — | — | — |
NCT07153445CT.gov Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC) | — | Recruiting | — | — | — |
NCT06930794CT.gov A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive | — | Recruiting | — | — | — |
NCT07031154CT.gov A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT07020221CT.gov A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors | — | Recruiting | — | — | — |
NCT07035392CT.gov Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC | — | Not Yet Recruiting | — | — | — |
NCT06745882CT.gov Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC | — | Recruiting | — | — | — |
NCT06946927CT.gov A Phase Ib Study of JMKX001899 in Combination With Other Therapies in Advanced NSCLC Harboring KRAS G12C Mutation | — | Recruiting | — | — | — |
NCT06364917CT.gov DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC | — | Recruiting | — | — | — |
NCT06963502CT.gov A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors | — | Not Yet Recruiting | — | — | — |
NCT06943820CT.gov AK129 Combination Therapy for Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06970782CT.gov Vebreltinib Plus PLB1004 Versus Platinum-based Doublet Chemotherapy in Patients With EGFRm, MET+, Locally Advanced or Metastatic NSCLC Following EGFR-TKI Failure | — | Not Yet Recruiting | — | — | — |
NCT06969612CT.gov A Study on the Efficacy and Safety of Golidocitinib Combined With Tislelizumab and Chemotherapy as First-line Treatment for Advanced NSCLC | — | Recruiting | — | — | — |
NCT07034391CT.gov A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status | — | Recruiting | — | — | — |
NCT06918782CT.gov Real-world Experience With Combination Chemotherapy and Osimertinib in Poor Prognostic Group of Metastatic EGFR-mutated Lung Adenocarcinoma | — | Not Yet Recruiting | — | — | — |
NCT06847334CT.gov A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX17 Vs. Keytruda® in the First-Line Treatment of Advanced Non-squamous Non-small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06875310CT.gov A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4) | — | Recruiting | — | — | — |
NCT07131319CT.gov SFRT+Tislelizumab+Platinum Chemotherapy for Unresectable Stage III NSCLC | — | Recruiting | — | — | — |
NCT06944470CT.gov JS207 Combined With Chemotherapy in Subjects With Stage II-III NSCLC | — | Not Yet Recruiting | — | — | — |
NCT06829459CT.gov A Study to Evaluate the Efficacy and Safety of Glumetinib Combined With Osimertinib Mesylate Versus Platinum-based Doublet Chemotherapy in Non-Small Cell Lung Cancer Patients After Resistance to EGFR-TKIs | — | Recruiting | — | — | — |
NCT06868732CT.gov Evaluation of JSKN016 Combination Therapy in Subjects With NSCLC | — | Recruiting | — | — | — |
NCT06939127CT.gov Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC | — | Recruiting | — | — | — |
NCT06917079CT.gov BBO-11818 in Adult Subjects With KRAS Mutant Cancer | — | Recruiting | — | — | — |
NCT06731907CT.gov A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01) | — | Recruiting | — | — | — |
NCT06927986CT.gov Phase III Trial of SYS6010 Versus Platinum-based Chemotherapy for EGFR-mutated NSCLC（SYNSTAR01） | — | Recruiting | — | — | — |
NCT06868836CT.gov Phase II Clinical Study of JS207 (PD-1/VEGF Bispecific Antibody) Combination Therapies in Patients With Driver Gene-Positive, Advanced Non-Small Cell Lung Cancer After Failure of TKI Therapy | — | Recruiting | — | — | — |
NCT06726265CT.gov Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004) | — | Active Not Recruiting | — | — | — |
NCT06883630CT.gov A Phase Ib Study of RC148 as Monotherapy or Combination for Locally Advanced or Metastatic NSCLC | — | Active Not Recruiting | — | — | — |
NCT06883136CT.gov Efficacy and Safety of Sintilimab Combined with Platinum-containing Double-agent Chemotherapy in First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Elderly Patients | — | Enrolling By Invitation | — | — | — |
NCT06848426CT.gov Xingbai Ji Formula Combined with Chemotherapy and Sintilimab in Metastatic Multi-Target Mutation-Negative Non-Small Cell Lung Cancer: a Clinical Trial | — | Not Yet Recruiting | — | — | — |
NCT06772623CT.gov Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations | — | Recruiting | — | — | — |
NCT06835569CT.gov A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations | — | Recruiting | — | — | — |
NCT06890182CT.gov Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage Ⅱ-ⅢB EGFR Sensitive Mutanted NSCLC | — | Not Yet Recruiting | — | — | — |
NCT07084610CT.gov Metabolic Biomarkers Predicting Response to Neoadjuvant Immunotherapy in Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06672068CT.gov A Study of TY-9591 With Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor NSCLC | — | Not Yet Recruiting | — | — | — |
NCT06837948CT.gov Neoadjuvant Chemotherapy Combined With Bispecific Antibody Versus Monoclonal Antibody in Locally Advanced NSCLC | — | Not Yet Recruiting | — | — | — |
NCT06754930CT.gov A Study of SHR-1826 for Injection in Combination With Other Antitumor Therapies in Subjects With NSCLC | — | Recruiting | — | — | — |
NCT06731413CT.gov Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC) | — | Recruiting | — | — | — |
NCT06431633CT.gov Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free. | — | Recruiting | — | — | — |
NCT06939595CT.gov A Study to Compare Effects and Safety of CT-P51 and Keytruda in Patients With Previously Untreated Metastatic Lung Cancer | — | Recruiting | — | — | — |
NCT06754644CT.gov A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLC | — | Recruiting | — | — | — |
NCT07005336CT.gov A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT06712316CT.gov Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer | — | Recruiting | — | — | — |
NCT06766591CT.gov Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs | — | Not Yet Recruiting | — | — | — |
NCT07039656CT.gov Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Non-small Cell Lung Cancer With or Without Prior Neoadjuvant Therapy | — | Recruiting | — | — | — |
NCT06735508CT.gov MRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06687369CT.gov A Study to Compare Pharmacokinetics, Efficacy, Safety, and Immunogenicity of MB12 (Proposed Pembrolizumab Biosimilar) to Keytruda® in Non-small Cell Lung Cancer (BENITO Study) | — | Recruiting | — | — | — |
NCT06667076CT.gov A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | — | Recruiting | — | — | — |
NCT06621563CT.gov Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06522360CT.gov Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2) | — | Withdrawn | — | — | — |
NCT06632327CT.gov Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06704724CT.gov A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene. | — | Terminated | — | — | — |
NCT06667908CT.gov A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC) | — | Recruiting | — | — | — |
NCT06704620CT.gov Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT06746870CT.gov A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT06671379CT.gov A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC | — | Active Not Recruiting | — | — | — |
NCT06627647CT.gov A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Non-squamous NSCLC | — | Recruiting | — | — | — |
NCT06659042CT.gov Perioperative Tislelizumab for Resectable II-IIIB(N2) KRAS-mutated Nonsquamous Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06956001CT.gov Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation | — | Recruiting | — | — | — |
NCT06692738CT.gov A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) | — | Recruiting | — | — | — |
NCT06784791CT.gov Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR) | — | Recruiting | — | — | — |
NCT06684873CT.gov A Multicenter, Single-arm, Open-label Study Evaluating the Safety and Efficacy of AK112 Combined With Chemotherapy as First-line Treatment for Non-squamous NSCLC Patients With BRAIN Metastases and Negative Driver Genes (IVO BRAIN) | — | Not Yet Recruiting | — | — | — |
NCT06594874CT.gov A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors | — | Not Yet Recruiting | — | — | — |
NCT06711900CT.gov A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06623422CT.gov A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) | — | Recruiting | — | — | — |
NCT06607185CT.gov A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT06564844CT.gov A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features | — | Active Not Recruiting | — | — | — |
NCT06434103CT.gov Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC | — | Withdrawn | — | — | — |
NCT06561386CT.gov A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1% | — | Recruiting | — | — | — |
NCT06417814CT.gov A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06652048CT.gov High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI | — | Recruiting | — | — | — |
NCT06463665CT.gov Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer | — | Recruiting | — | — | — |
NCT06970639CT.gov A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases | — | Recruiting | — | — | — |
NCT06561685CT.gov A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT06333951CT.gov Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104). | — | Active Not Recruiting | — | — | — |
NCT06604351CT.gov Bronchoscopic Cryoablation Combined With Chemo-Immunotherapy in NSCLC With Central Airway Obstruction | — | Not Yet Recruiting | — | — | — |
NCT06452277CT.gov A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2) | — | Recruiting | — | — | — |
NCT06448754CT.gov Volrustomig Priming Regimens Exploratory Phase II Platform Study | — | Recruiting | — | — | — |
NCT06617936CT.gov Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer. | — | Recruiting | — | — | — |
NCT06467617CT.gov Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC | — | Recruiting | — | — | — |
NCT06416410CT.gov JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation | — | Recruiting | — | — | — |
NCT06574347CT.gov Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC. | — | Recruiting | — | — | — |
NCT06532149CT.gov ERectile Dysfunctions, gOnadotoxicity and Sexual Health Assessment in Men With Lung Cancer | — | Recruiting | — | — | — |
NCT06532591CT.gov Neoadjuvant/Adjuvant Cadonilimab Plus Chemotherapy in Patients With Resectable PD-L1 Negative NSCLC | — | Recruiting | — | — | — |
NCT06512051CT.gov A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06430437CT.gov A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations | — | Recruiting | — | — | — |
NCT06412471CT.gov A Phase II Study of SSGJ-707 Combination Therapy in Advanced NSCLC Patients | — | Unknown | — | — | — |
NCT06280196CT.gov A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC | — | Terminated | — | — | — |
NCT06096844CT.gov Chemotherapy Combined With Immunotherapy Versus Immunotherapy Alone for Older Adults With Stage IIIB-IV Lung Cancer, The ACHIEVE Trial | — | Recruiting | — | — | — |
NCT06161441CT.gov A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery | — | Active Not Recruiting | — | — | — |
NCT06046495CT.gov A Study of the Oral EGFR Inhibitor PLB1004 in Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06514027CT.gov Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations | — | Not Yet Recruiting | — | — | — |
NCT06475755CT.gov Neoadjuvant/Adjuvant Tislelizumab Combined With Anlotinib and Platinum Doublet Chemotherapy With Resectable NSCLC | — | Not Yet Recruiting | — | — | — |
NCT06447662CT.gov A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation. | — | Recruiting | — | — | — |
NCT06734182CT.gov Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06305754CT.gov Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) | — | Active Not Recruiting | — | — | — |
NCT06422143CT.gov Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023] | — | Recruiting | — | — | — |
NCT06093503CT.gov Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein | — | Withdrawn | — | — | — |
NCT06382116CT.gov A Study Comparing BL-B01D1 With Platinum Based Chemotherapy in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer(PANKU-Lung01) | — | Active Not Recruiting | — | — | — |
NCT06400472CT.gov A Study of LY4170156 in Participants With Selected Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06424899CT.gov A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC | — | Recruiting | — | — | — |
NCT06391008CT.gov Immunosensitized Radiotherapy Combined With Evoximab (AK112) and Chemotherapy Neoadjuvant Therapy for Stage II-III Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT06380348CT.gov JMT101 in Combination With Osimertinib, Versus Cisplatin-pemetrexed in Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Exon 20ins Mutations | — | Not Yet Recruiting | — | — | — |
NCT06299371CT.gov Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations | — | Not Yet Recruiting | — | — | — |
NCT06236438CT.gov Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | — | Recruiting | — | — | — |
NCT06008093CT.gov A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS | — | Active Not Recruiting | — | — | — |
NCT06312137CT.gov A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019) | — | Recruiting | — | — | — |
NCT06300424CT.gov Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC | — | Active Not Recruiting | — | — | — |
NCT05911308CT.gov Abequolixron (RGX-104) and Durvalumab in Lung Cancer | — | Terminated | — | — | — |
NCT06253871CT.gov A Phase 1/1b Study of IAM1363 in HER2 Cancers | — | Recruiting | — | — | — |
NCT05116462CT.gov Neoadjuvant and Adjuvant Therapy Studies of Sindilizumab in Resectable Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT06297811CT.gov Myeloprotection With Trilaciclib in Pan-cancer Population | — | Not Yet Recruiting | — | — | — |
NCT06335355CT.gov A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients | — | Not Yet Recruiting | — | — | — |
NCT06151574CT.gov Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment | — | Active Not Recruiting | — | — | — |
NCT06246110CT.gov A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC | — | Active Not Recruiting | — | — | — |
NCT06758557CT.gov A Study to Evaluate the Safety and Efficacy of HB0025 Injection in Patients With Advanced Solid Tumor | — | Recruiting | — | — | — |
NCT06162221CT.gov Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC | — | Recruiting | — | — | — |
NCT06357598CT.gov Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT06110663CT.gov A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy | — | Unknown | — | — | — |
NCT06119581CT.gov A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT06109402CT.gov Perioperative Immunotherpay Versus Adjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT05689671CT.gov Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma | — | Active Not Recruiting | — | — | — |
NCT05812534CT.gov Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain Metastases | — | Unknown | — | — | — |
NCT06281964CT.gov Efficacy and Safety Evaluation of PLB1004 in Patients With Non-squamous NSCLC Harboring EGFR Exon 20 Insertion. | — | Enrolling By Invitation | — | — | — |
NCT06094296CT.gov A Study of BMS-986315 and Nivolumab in Combination With Chemotherapy in Participants With First-line Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT06091943CT.gov Study to Evaluate the Bioavailability of Tislelizumab Via Subcutaneous Injection in First-Line Treatment of Participants With Advanced or Metastatic Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05990127CT.gov A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer | — | Not Yet Recruiting | — | — | — |
NCT05948462CT.gov Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib | — | Withdrawn | — | — | — |
NCT06047379CT.gov Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | — | Recruiting | — | — | — |
NCT05984277CT.gov A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer. | — | Active Not Recruiting | — | — | — |
NCT06667154CT.gov Efficacy Analysis of Neoadjuvant Treatment in Lung Cancer Using Low-dose Nivolumab Combined With Chemotherapy | — | Recruiting | — | — | — |
NCT05715229CT.gov Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy | — | Recruiting | — | — | — |
NCT06020989CT.gov Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy | — | Unknown | — | — | — |
NCT05841472CT.gov Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT05978401CT.gov Safety, Tolerability, and Efficacy of GLS-012 and GLS-010 in Patients With Advanced Non-Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT05746481CT.gov Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases | — | Terminated | — | — | — |
NCT06328049CT.gov A Study of Trilaciclib Combined With Chemotherapy in the Treatment of NSCLC | — | Unknown | — | — | — |
NCT06331650CT.gov A Single-arm Pilot Study of First-line Treatment With Carbognilumab Combined With Chemotherapy in Patients With STK11-mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT05800015CT.gov A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT06001151CT.gov Cadonilimab (AK104) Plus Chemotherapy as First-line Treatment in Non-squamous Non-Small Cell Lung Cancer (NSCLC) Patients With Programmed Cell Death Ligand 1 (PD-L1) Negative | — | Recruiting | — | — | — |
NCT05962021CT.gov Neoadjuvant Toripalimab for Non-squamous NSCLC With EGFR Mutation | — | Not Yet Recruiting | — | — | — |
NCT05849246CT.gov The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) | — | Terminated | — | — | — |
NCT05791097CT.gov Study of Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Platinum-based Doublet Chemotherapy as First-line Treatment for Participants With Locally Advanced or Metastatic NSCLC. | — | Withdrawn | — | — | — |
NCT06015503CT.gov A Phase Ⅱ Study Assessing the Safety and Efficacy of PLB1004 in EGFR ex20ins Mutation Patients With Advanced and Metastatic Non-small Cell Lung Cancer(NSCLC) | — | Active Not Recruiting | — | — | — |
NCT05904379CT.gov AK112 and AK104 With or Without Chemotherapy in Advanced Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05624996CT.gov Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT05985655CT.gov Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT06424821CT.gov Cadonilimab Plus Chemotherapy as First-line Treatment for PD-L1 Negative NSCLC | — | Unknown | — | — | — |
NCT05891080CT.gov Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial | — | Not Yet Recruiting | — | — | — |
NCT05751187CT.gov Pembrolizumab Plus Bevacizumab and Chemotherapy for Non-Squamous NSCLC Patients | — | Active Not Recruiting | — | — | — |
NCT05870319CT.gov A Phase III Study of SKB264 for EGFR Mutant NSCLC Patients | — | Active Not Recruiting | — | — | — |
NCT05756972CT.gov A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With NSCLC | — | Active Not Recruiting | — | — | — |
NCT05834348CT.gov A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. | — | Completed | — | — | — |
NCT05789082CT.gov A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation | — | Recruiting | — | — | — |
NCT06343064CT.gov Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI | — | Recruiting | — | — | — |
NCT06212752CT.gov A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension | — | Active Not Recruiting | — | — | — |
NCT06341660CT.gov To Evaluate the Safety and Tolerability of Carbognilumab Combined With Chemotherapy as the First-line Treatment for Patients With KEAP1 Mutated Advanced or Postoperative Recurrent Non-small Cell Lung Cancer (NSCLC) | — | Unknown | — | — | — |
NCT05882513CT.gov Serplulimab Combined With Chemotherapy in Patients With Resectable Non-small-cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT06136910CT.gov Oncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT05501665CT.gov Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer | — | Recruiting | — | — | — |
NCT06334757CT.gov Serplulimab Plus Bevacizumab and Chemotherapy for EGFR-mutant Metastatic NSCLC Patients After EGFR-TKI Treatment Failure | — | Unknown | — | — | — |
NCT06396065CT.gov Phase III Study of AK112 for NSCLC Patients | — | Active Not Recruiting | — | — | — |
NCT05767892CT.gov YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations | — | Not Yet Recruiting | — | — | — |
NCT05847764CT.gov Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations | — | Unknown | — | — | — |
NCT05816252CT.gov A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003) | — | Active Not Recruiting | — | — | — |
NCT05786430CT.gov Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib | — | Active Not Recruiting | — | — | — |
NCT05800340CT.gov Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC | — | Recruiting | — | — | — |
NCT05633667CT.gov Study of Novel Treatment Combinations in Patients With Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05775289CT.gov A Study of Tobemstomig Plus Platinum-Based Chemotherapy vs Pembrolizumab Plus Platinum-Based Chemotherapy in Participants With Previously Untreated Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05766800CT.gov Induction Therapy With PD-1 Antibody Combined With Platinum-based Doublet Chemotherapy for Locally-advanced Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT05611879CT.gov Neoadjuvant of Tislelizumab Combined With Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC | — | Unknown | — | — | — |
NCT05577702CT.gov Efficacy, Safety, and Pharmacodynamics of Tislelizumab Monotherapy and Multiple Tislelizumab-based Immunotherapy Combinations in Participants With Resectable Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT05635708CT.gov A Study of Tislelizumab in Combination With Investigational Agents in Participants With Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05469178CT.gov A Clinical Study of Bemcentinib With Standard of Care Chemoimmunotherapy in Untreated Advanced/Metastatic Non-small Cell Lung Cancer Patients With a Mutation in the STK11 Gene | — | Terminated | — | — | — |
NCT05456256CT.gov A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma | — | Recruiting | — | — | — |
NCT05741021CT.gov A Phase II Study of Rulonilimab Combined With Chemotherapy in the First-Line Treatment for Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | — | Unknown | — | — | — |
NCT05800587CT.gov Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer | — | Recruiting | — | — | — |
NCT05816499CT.gov Cadonilimab in Patients (Pts) With Advanced Non-small Cell Lung Cancer (NSCLC) | — | Active Not Recruiting | — | — | — |
NCT05722015CT.gov A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77) | — | Active Not Recruiting | — | — | — |
NCT05636267CT.gov Study of AK119 and AK112 With or Without Chemotherapy for NSCLC Patients | — | Terminated | — | — | — |
NCT05597800CT.gov Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid Syndrome | — | Not Yet Recruiting | — | — | — |
NCT05555732CT.gov Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07) | — | Active Not Recruiting | — | — | — |
NCT05687266CT.gov Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations | — | Active Not Recruiting | — | — | — |
NCT05198830CT.gov Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT05493501CT.gov Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT05668988CT.gov A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) | — | Active Not Recruiting | — | — | — |
NCT05487391CT.gov A Study of QL1706 Combined With Platinum-containing Chemotherapy in Adjuvant Treatment of Stage II-IIIB Non-small Cell Lung Cancer After Complete Surgical Resection. | — | Recruiting | — | — | — |
NCT05579366CT.gov Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) | — | Recruiting | — | — | — |
NCT06241807CT.gov Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC | — | Recruiting | — | — | — |
NCT05609578CT.gov Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation | — | Recruiting | — | — | — |
NCT05498428CT.gov A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT05502237CT.gov Zimberelimab and Domvanalimab in Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy in Patients With Untreated Metastatic Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05543629CT.gov A Study of BMS-986442 With Nivolumab With or Without Chemotherapy in Solid Tumors and Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT05504278CT.gov Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation | — | Recruiting | — | — | — |
NCT05386888CT.gov A Trial of GFH018 and Toripalimab in Combination With Concurrent Chemoradiotherapy in Stage III NSCLC Chemoradiotherapy in Stage III NSCLC | — | Completed | — | — | — |
NCT04638582CT.gov Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT05403385CT.gov Study of Inupadenant (EOS100850) With Chemotherapy as Second Line Treatment for Nonsquamous Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05431270CT.gov Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study) | — | Recruiting | — | — | — |
NCT05261399CT.gov Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment | — | Active Not Recruiting | — | — | — |
NCT05477615CT.gov Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases | — | Unknown | — | — | — |
NCT05377658CT.gov AK104 With Chemotherapy as Neoadjuvant and Adjuvant Therapy for Resectable Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT05364645CT.gov Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT05258279CT.gov Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations | — | Active Not Recruiting | — | — | — |
NCT05142189CT.gov Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT05407155CT.gov Bevacizumab Plus Nab-paclitaxel and Platinum for Immunotherapy-treated Non-squamous Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05244213CT.gov Neoadjuvant Immunotherapy in EGFR-mutant Localized NSCLC | — | Active Not Recruiting | — | — | — |
NCT05186974CT.gov Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) | — | Active Not Recruiting | — | — | — |
NCT04967417CT.gov Pembrolizumab With Standard Cytotoxic Chemotherapy in Treatment Naive NSCLC Patients With Asymptomatic Brain Metastases | — | Completed | — | — | — |
NCT05351788CT.gov SKB264 Combinatiton Therapy in Patients With Advanced or Metastatic Non-small Cell Lung Cancer. | — | Recruiting | — | — | — |
NCT05200481CT.gov Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK) | — | Active Not Recruiting | — | — | — |
NCT05334277CT.gov Furmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNA | — | Recruiting | — | — | — |
NCT05298423CT.gov Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006) | — | Active Not Recruiting | — | — | — |
NCT05061550CT.gov Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT05226598CT.gov Study of Pembrolizumab/Vibostolimab Coformulation (MK-7684A) in Combination With Chemotherapy Versus Pembrolizumab Plus Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (MK-7684A-007/KEYVIBE-007) | — | Completed | — | — | — |
NCT05241873CT.gov (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations | — | Terminated | — | — | — |
NCT05209256CT.gov Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLC | — | Unknown | — | — | — |
NCT05247684CT.gov AK112 Neoadjuvant/Adjuvant Treatment for Resectable NSCLC | — | Active Not Recruiting | — | — | — |
NCT06268210CT.gov Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT04956146CT.gov Fruquintinib Combined With Sintilimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT05098132CT.gov Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers | — | Recruiting | — | — | — |
NCT05346952CT.gov A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC). | — | Unknown | — | — | — |
NCT05153408CT.gov (HARMONY) Study of BLU-701 in EGFR-mutant NSCLC | — | Terminated | — | — | — |
NCT05298176CT.gov Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors | — | Completed | — | — | — |
NCT04856176CT.gov A Study of Sargramostim Plus Pembrolizumab with or Without Pemetrexed in Patients with Advance Non-small Cell Lung Cancer After Completion of Chemoimmunotherapy | — | Terminated | — | — | — |
NCT05132985CT.gov Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma | — | Not Yet Recruiting | — | — | — |
NCT05312840CT.gov Efficacy and Safety of Conventional and Low-dose Platinum Gemcitabine Combined With Sintilimab With Delayed Administration in First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT04769388CT.gov Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib | — | Active Not Recruiting | — | — | — |
NCT04786964CT.gov Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC | — | Terminated | — | — | — |
NCT05003037CT.gov Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer | — | Unknown | — | — | — |
NCT04430933CT.gov A Safety and Tolerability Study of NC318 in Combination With Chemotherapy for Subjects With Advanced or Metastatic NSCLC | — | Withdrawn | — | — | — |
NCT05136846CT.gov Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT05015608CT.gov Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification | — | Completed | — | — | — |
NCT04136535CT.gov Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC | — | Recruiting | — | — | — |
NCT05012254CT.gov Nivolumab and Ipilimumab Plus Chemotherapy for Patients With Stage IV Lung Cancer With Brain Metastases | — | Active Not Recruiting | — | — | — |
NCT04988295CT.gov A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure | — | Active Not Recruiting | — | — | — |
NCT05014815CT.gov Ociperlimab With Tislelizumab and Chemotherapy in Participants With Untreated Metastatic Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT05281406CT.gov Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG) | — | Recruiting | — | — | — |
NCT05117476CT.gov A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05048797CT.gov A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations | — | Active Not Recruiting | — | — | — |
NCT05104788CT.gov A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT04993677CT.gov A Study of SEA-CD40 Given With Other Drugs in Cancers | — | Completed | — | — | — |
NCT04989322CT.gov Pembrolizumab, Lenvatinib and Chemotherapy After TKIs in NSCLC | — | Unknown | — | — | — |
NCT04765709CT.gov Durvalumab and Chemotherapy Induction Followed by Durvalumab and Radiotherapy in Large Volume Stage III NSCLC | — | Terminated | — | — | — |
NCT04816214CT.gov Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy | — | Terminated | — | — | — |
NCT04989283CT.gov Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT05055583CT.gov Toripalimab in Combination With Platinum-based Chemotherapy for Mutation-negative Stage IV Oligometastatic NSCLC | — | Unknown | — | — | — |
NCT04585490CT.gov Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC | — | Recruiting | — | — | — |
NCT04943029CT.gov Neoadjuvant Immunotherapy and Chemotherapy Followed by Surgery in Unresectable Stage Ⅲ NSCLC | — | Unknown | — | — | — |
NCT04956692CT.gov Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86) | — | Active Not Recruiting | — | — | — |
NCT04846634CT.gov Penpulimab-based Combination Neoadjuvant/Adjuvant Therapy for Patients With Resectable Locally Advanced Non-small Cell Lung Cancer: a Phase II Clinical Study (ALTER-L043) | — | Not Yet Recruiting | — | — | — |
NCT05507606CT.gov Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations | — | Unknown | — | — | — |
NCT04942301CT.gov PK Study for Endostar Continuous Intravenous Infusion in NSCLC Patients With 1st-line Platinum Based Chemotherapy | — | Unknown | — | — | — |
NCT04956640CT.gov Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C) | — | Active Not Recruiting | — | — | — |
NCT04872634CT.gov A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment | — | Unknown | — | — | — |
NCT04892953CT.gov Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy | — | Recruiting | — | — | — |
NCT04611776CT.gov A Study Evaluating the Efficacy and Safety of Adjuvant Platinum-Doublet Chemotherapy, With or Without Atezolizumab, in Patients Who Are ctDNA Positive After Complete Surgical Resection of Stage IB to Select IIIB Non-Small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT04971187CT.gov Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT04870112CT.gov A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT04776447CT.gov Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO) | — | Active Not Recruiting | — | — | — |
NCT04846452CT.gov Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC | — | Unknown | — | — | — |
NCT04999761CT.gov AB122 Platform Study | — | Recruiting | — | — | — |
NCT04768075CT.gov Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC | — | Completed | — | — | — |
NCT04466917CT.gov A Study of ABP 215 Versus Bevacizumab in Chinese Subjects With Advanced Non-Squamous Non-Small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT04646837CT.gov Mechanism of Response to IMFINZI Neoadjuvant Therapy in Non-small Cell Lung Cancer Patients Based on Multiple-omics Models | — | Unknown | — | — | — |
NCT04832854CT.gov A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT04585477CT.gov Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E) | — | Recruiting | — | — | — |
NCT04470674CT.gov Study of Durvalumab or Durvalumab Plus Chemotherapy in Kras Mutation Positive and PD-L1 High (≥ 50%) NSCLC Patients | — | Withdrawn | — | — | — |
NCT04725448CT.gov Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma | — | Unknown | — | — | — |
NCT05044728CT.gov Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest. | — | Unknown | — | — | — |
NCT04836728CT.gov Phase II Study of Chemotherapy and PD-1 Inhibitor Combination With Autologous CIK Cell Immunotherapy to Treat Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT04695925CT.gov Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations | — | Active Not Recruiting | — | — | — |
NCT04665206CT.gov Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT04837716CT.gov Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT04686305CT.gov Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC | — | Recruiting | — | — | — |
NCT04828395CT.gov Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT04623775CT.gov A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT04762030CT.gov Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study | — | Unknown | — | — | — |
NCT04736173CT.gov Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT04612751CT.gov Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT04736823CT.gov A Trial of AK112 (PD1/VEGF Bispecific) in Combination With Chemotherapy in Patients With NSCLC | — | Active Not Recruiting | — | — | — |
NCT04619433CT.gov A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC. | — | Terminated | — | — | — |
NCT04982549CT.gov A Study to Evaluate the Safety of Concurrent Durvalumab With CRT Followed by Durvalumab for Chinese Unresectable Stage III NSCLC | — | Unknown | — | — | — |
NCT04865250CT.gov Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC | — | Recruiting | — | — | — |
NCT04547504CT.gov PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 % | — | Active Not Recruiting | — | — | — |
NCT04351555CT.gov A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT04619797CT.gov A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT04706949CT.gov Pyrotinib Combined With Pemetrexed Plus Carboplatin in the First-line Treatment | — | Unknown | — | — | — |
NCT04512430CT.gov Neo-DIANA: Neoadjuvant Treatment for EGFR Mutated Patients | — | Terminated | — | — | — |
NCT04647344CT.gov A Study of AK104 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT04533451CT.gov Testing the Effects of MK-3475 (Pembrolizumab) With or Without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older With Advanced Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT04644068CT.gov Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies | — | Active Not Recruiting | — | — | — |
NCT04580498CT.gov A Trial of SHR-1701 With or Without Chemotherapy in Patients With Stage III NSCLC | — | Unknown | — | — | — |
NCT04517526CT.gov Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study | — | Unknown | — | — | — |
NCT04524689CT.gov Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC | — | Terminated | — | — | — |
NCT04538664CT.gov A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions | — | Active Not Recruiting | — | — | — |
NCT04586465CT.gov Dynamic PET/CT Evaluated the Response of Neoadjuvant Anti-PD1 Combination With Chemotherapy for Ⅱa-Ⅲb NSCLC | — | Unknown | — | — | — |
NCT04592666CT.gov Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer | — | Unknown | — | — | — |
NCT04455594CT.gov Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC | — | Unknown | — | — | — |
NCT04500717CT.gov Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation | — | Unknown | — | — | — |
NCT04500704CT.gov Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC | — | Unknown | — | — | — |
NCT04245085CT.gov ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma | — | Completed | — | — | — |
NCT04750083CT.gov HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT04452214CT.gov A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors | — | Completed | — | — | — |
NCT04507217CT.gov Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous NSCLC | — | Completed | — | — | — |
NCT04526691CT.gov Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02) | — | Active Not Recruiting | — | — | — |
NCT04205812CT.gov Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05347628CT.gov Assessing the Safety and Efficacy of PLB1004 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | — | Unknown | — | — | — |
NCT04416035CT.gov A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC | — | Unknown | — | — | — |
NCT04541251CT.gov Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC | — | Unknown | — | — | — |
NCT04332367CT.gov Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance | — | Recruiting | — | — | — |
NCT04203511CT.gov INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301) | — | Withdrawn | — | — | — |
NCT04265534CT.gov KEAPSAKE: A Study of Telaglenastat (CB-839) With Standard-of-Care Chemoimmunotherapy in 1L KEAP1/NRF2-Mutated, Nonsquamous NSCLC | — | Terminated | — | — | — |
NCT04222972CT.gov A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT04405674CT.gov Tislelizumab Combined With Chemotherapy With or Without Bevacizumab in TKI-Resistant EGFR-Mutated Non-squamous NSCLC | — | Unknown | — | — | — |
NCT04316364CT.gov A Trial of SHR-1316/Placebo in Combination With Chemotherapy in Patients With Resectable NSCLC | — | Recruiting | — | — | — |
NCT04422392CT.gov Neoadjuvant PD-1 Antibody Plus Chemotherapy in Resectable Stage IIIA-N2 Non-Small-Cell Lung Cancer | — | Terminated | — | — | — |
NCT04470076CT.gov Neoadjuvant Afatinib Combination With Chemotherapy for Stage Ⅱa-Ⅲb NSCLC With EGFR Activating Mutation | — | Unknown | — | — | — |
NCT04380636CT.gov Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) | — | Active Not Recruiting | — | — | — |
NCT04459611CT.gov Neoadjuvant of Sintilimab Combined With Chemotherapy for Resectable NSCLC（neoSCORE） | — | Unknown | — | — | — |
NCT04699721CT.gov Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLC | — | Active Not Recruiting | — | — | — |
NCT04253964CT.gov Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy | — | Recruiting | — | — | — |
NCT04453423CT.gov Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer. | — | Unknown | — | — | — |
NCT04163432CT.gov Staggered, Chemo-Immunotherapy With Durvalumab, MEDI4736 Pemetrexed & Carboplatin (PC) for Metastatic Non-Squamous NSCLC | — | Active Not Recruiting | — | — | — |
NCT04267848CT.gov Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) | — | Recruiting | — | — | — |
NCT04203485CT.gov Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC) | — | Unknown | — | — | — |
NCT04325698CT.gov A BRIDGING STUDY OF PF-06439535 (CN) PLUS PACLITAXEL-CARBOPLATIN VERSUS BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN IN NSCLC | — | Terminated | — | — | — |
NCT04389632CT.gov A Study of Sigvotatug Vedotin in Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT04379635CT.gov Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC) | — | Active Not Recruiting | — | — | — |
NCT04410796CT.gov Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers | — | Recruiting | — | — | — |
NCT04371796CT.gov Sintilimab (IBI308) in the Neoadjuvant Treatment of Patients With Resectable II-IIIA NSCLC | — | Unknown | — | — | — |
NCT04092283CT.gov Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT05318443CT.gov A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT03965689CT.gov Testing the Combination of MLN4924 (Pevonedistat), Carboplatin, and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Who Have Previously Been Treated With Immunotherapy | — | Active Not Recruiting | — | — | — |
NCT04194203CT.gov A Study of Bevacizumab, Carboplatin, and Paclitaxel or Pemetrexed With or Without Atezolizumab in Chemotherapy-Naïve Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (IMpower151) | — | Completed | — | — | — |
NCT04158440CT.gov Phase III Study of Toripalimab Versus Placebo Plus Chemotherapy in Resectable NSCLC | — | Active Not Recruiting | — | — | — |
NCT04262869CT.gov Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT04326153CT.gov Neoadjuvant Immunotherapy Plus Chemotherapy for Potentially Resectable Stage IIIA/IIIB Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT04194944CT.gov A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT04211090CT.gov Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLC | — | Unknown | — | — | — |
NCT04166487CT.gov Plasma-Adapted First-Line Pembro In NSCLC | — | Active Not Recruiting | — | — | — |
NCT04129502CT.gov TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations | — | Active Not Recruiting | — | — | — |
NCT04165070CT.gov KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A) | — | Recruiting | — | — | — |
NCT04198766CT.gov Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | — | Active Not Recruiting | — | — | — |
NCT03952403CT.gov A Study of HLX10 in Combination With Carboplatin Plus (+) Pemetrexed With or Without HLX04 Compared With Carboplatin+Pemetrexed in 1L Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | — | Unknown | — | — | — |
NCT04153734CT.gov Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLC | — | Not Yet Recruiting | — | — | — |
NCT03965468CT.gov Immunotherapy, Chemotherapy, Radiotherapy and Surgery for Synchronous Oligo-metastatic NSCLC | — | Active Not Recruiting | — | — | — |
NCT03390686CT.gov A Trial to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity of HD204 to Avastin® in Advanced Non-squamous Non-small Cell Lung Cancer Patients | — | Active Not Recruiting | — | — | — |
NCT04716933CT.gov Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006)-China Extension Study | — | Completed | — | — | — |
NCT04108013CT.gov A Study of SHR-1210 in Combination With Carboplatin+Paclitaxel-albumin in Subjects With Resectable NSCLC | — | Unknown | — | — | — |
NCT04042558CT.gov A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies | — | Completed | — | — | — |
NCT04083599CT.gov GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04054531CT.gov Study of KN046 With Chemotherapy in First Line Advanced NSCLC | — | Unknown | — | — | — |
NCT04077463CT.gov A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT04022876CT.gov A Study of ALRN-6924 for the Prevention of Chemotherapy-induced Side Effects (Chemoprotection) | — | Terminated | — | — | — |
NCT03991403CT.gov Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC | — | Unknown | — | — | — |
NCT04063449CT.gov Endostar/PD-1 Inhibitors Combined With PP for Advanced NSCLC | — | Unknown | — | — | — |
NCT04439890CT.gov A Efficacy and Safety Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy Versus Placebo Combined With Chemotherapy as First-line Treatment in Subjects With Advanced Non-squamous Cell Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT04304248CT.gov Neoadjuvant Toripalimab Plus Platinum-based Doublet for Stage III Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT03737994CT.gov Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT03977194CT.gov Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy | — | Active Not Recruiting | — | — | — |
NCT03920839CT.gov INCMGA00012 Plus Chemotherapy in Participants With Advanced Solid Tumors (POD1UM-105) | — | Withdrawn | — | — | — |
NCT03777124CT.gov Phase II Study of SHR-1210(Anti-PD-1 Antibody) Combination With Apatinib Versus Pemetrexed and Carboplatin in Subjects With KRAS Mutant Stage IV Non-squamous Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT04035486CT.gov A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2) | — | Active Not Recruiting | — | — | — |
NCT03976323CT.gov Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006) | — | Completed | — | — | — |
NCT03944772CT.gov Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) | — | Active Not Recruiting | — | — | — |
NCT03916419CT.gov Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT04840290CT.gov A Neoadjuvant Study of Sintilimab Plus Platinum Doublet Chemotherapy in IIIA(N2) Stage NSCLC | — | Unknown | — | — | — |
NCT03987867CT.gov Study of Autologous CIK Cell Immunotherapy Combination With PD-1 Inhibitor and Chemotherapy in the Advanced NSCLC | — | Unknown | — | — | — |
NCT03945227CT.gov Clinical Trial for Evaluating Efficacy and Safety of PDR001 in Concurrent Plus Consolidation Versus Consolidation Only in Addition to Standard Chemoradiotherapy in Unresectable Stage III NSCLC Patients (PASTURE) | — | Withdrawn | — | — | — |
NCT03912389CT.gov Efficacy and Safety of BCD-100 (Anti-PD-1) in Combination With Platinum-Based Chemotherapy as First Line Treatment in Patients With Advanced Non-Squamous NSCLC | — | Unknown | — | — | — |
NCT03893955CT.gov A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and/or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03645928CT.gov Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors | — | Terminated | — | — | — |
NCT03838848CT.gov KN046 in Patients With Advanced Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT03840902CT.gov M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT03793179CT.gov Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT03840915CT.gov M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT03846310CT.gov A Study to Evaluate Immunotherapy Combinations in Participants With Lung Cancer | — | Completed | — | — | — |
NCT03829319CT.gov Safety and Efficacy Study of Pemetrexed + Platinum Chemotherapy + Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-7902-006/E7080-G000-315/LEAP-006) | — | Completed | — | — | — |
NCT03790228CT.gov Anlotinib Combined With Pemetrexed And Carboplatin as First-line Treatment in Advanced Nonsquamous NSCLC | — | Unknown | — | — | — |
NCT03799601CT.gov Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC | — | Unknown | — | — | — |
NCT03792074CT.gov To Evaluate the Efficacy and Safety of SCT510 in the Treatment of Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT03819465CT.gov A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC | — | Active Not Recruiting | — | — | — |
NCT03559049CT.gov Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT03631199CT.gov Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects | — | Terminated | — | — | — |
NCT03775486CT.gov Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION) | — | Active Not Recruiting | — | — | — |
NCT03866993CT.gov A Study of Anti-PD-1 AK105 in Patients With Metastatic Squamous Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT03800134CT.gov A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT03866980CT.gov A Study of Anti-PD-1 AK105 in Patients With Metastatic Nonsquamous Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT02905591CT.gov A Phase 2 Study Adding Ascorbate to Chemotherapy and Radiation Therapy for NSCLC | — | Active Not Recruiting | — | — | — |
NCT03713944CT.gov Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT03672136CT.gov Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients | — | Unknown | — | — | — |
NCT03664024CT.gov Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782) | — | Completed | — | — | — |
NCT03631784CT.gov A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799) | — | Completed | — | — | — |
NCT03647956CT.gov Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors | — | Unknown | — | — | — |
NCT03656393CT.gov To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma | — | Unknown | — | — | — |
NCT03562871CT.gov IO102 With Pembrolizumab, With or Without Chemotherapy, as First-line Treatment of Metastatic NSCLC | — | Completed | — | — | — |
NCT03636685CT.gov Study of Anlotinib Plus Chemotherapy as the First-line Treatment in Patients With Advanced NSCLC | — | Unknown | — | — | — |
NCT03594747CT.gov A Study of Tislelizumab in Combination With Chemotherapy Versus Chemotherapy in Advanced Lung Cancer | — | Completed | — | — | — |
NCT03663205CT.gov A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT03574402CT.gov Phase II Umbrella Study Directed by Next Generation Sequencing | — | Unknown | — | — | — |
NCT03515837CT.gov Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789) | — | Completed | — | — | — |
NCT03485209CT.gov Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03574649CT.gov QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT03498222CT.gov Study in Patients With Tumours Requiring Arginine to Assess ADI-PEG 20 With Atezolizumab, Pemetrexed and Carboplatin | — | Withdrawn | — | — | — |
NCT03520686CT.gov Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT03380871CT.gov A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer | — | Completed | — | — | — |
NCT03509012CT.gov Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03456063CT.gov A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030) | — | Completed | — | — | — |
NCT03513666CT.gov A Study of Toripalimab+ Pemetrexed Plus Carboplatin in Patients With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment | — | Completed | — | — | — |
NCT03519971CT.gov Study of Durvalumab Given With Chemoradiation Therapy in Patients With Unresectable Non-small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT03396445CT.gov Study of Boserolimab (MK-5890) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Adults With Advanced Solid Tumors (MK-5890-001) | — | Completed | — | — | — |
NCT03296163CT.gov A Study Comparing MB02 and Avastin® in Subjects With Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT05169801CT.gov To Compare the Efficacy and Safety of BP102 vs. Avastin® in Combination With Paclitaxel/Carboplatin in First-line Treatment of Advanced or Relapsed NSCLC | — | Completed | — | — | — |
NCT03413358CT.gov Clinical Trial for Post-marketing Evaluation of Sheng Bai Oral Liquid | — | Unknown | — | — | — |
NCT03337698CT.gov A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) | — | Terminated | — | — | — |
NCT03317496CT.gov Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies | — | Terminated | — | — | — |
NCT03345810CT.gov Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION) | — | Completed | — | — | — |
NCT03329911CT.gov A Comparative Study of BAT1706 and EU Avastin® in Patients With Advanced Non Squamous Non Small Cell Lung Cancer | — | Completed | — | — | — |
NCT03267654CT.gov Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance | — | Unknown | — | — | — |
NCT03307785CT.gov Study of Niraparib, TSR-022, Bevacizumab, and Platinum-Based Doublet Chemotherapy in Combination With TSR-042 | — | Completed | — | — | — |
NCT03242915CT.gov Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents | — | Completed | — | — | — |
NCT03177291CT.gov Pirfenidone Combined With Standard First-Line Chemotherapy in Advanced-Stage Lung NSCLC | — | Completed | — | — | — |
NCT02920450CT.gov Study of Paclitaxel, Carboplatin, and PF-05212384 in Advanced or Metastatic NSCLC (UF-STO-LUNG-002) | — | Terminated | — | — | — |
NCT03178552CT.gov A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) | — | Active Not Recruiting | — | — | — |
NCT03267316CT.gov A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors | — | Completed | — | — | — |
NCT03215706CT.gov A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC | — | Completed | — | — | — |
NCT03196986CT.gov mil60 Versus Bevacizumab in Patients With Treatment-naïve Non-squamous Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT03201146CT.gov Apatinib Combine With Platinum-Based Doublet Chemotherapy for First-line Treatment of Advanced NSCLC | — | Unknown | — | — | — |
NCT03158129CT.gov Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT03117049CT.gov Study of ONO-4538 in Non-Squamous Non-Small Cell Lung Cancer (TASUKI-52) | — | Completed | — | — | — |
NCT03138889CT.gov Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors | — | Terminated | — | — | — |
NCT03164616CT.gov Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON). | — | Active Not Recruiting | — | — | — |
NCT03088540CT.gov Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT03064854CT.gov PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients | — | Terminated | — | — | — |
NCT03134872CT.gov A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC | — | Completed | — | — | — |
NCT03141359CT.gov Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC | — | Active Not Recruiting | — | — | — |
NCT03875092CT.gov A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study | — | Completed | — | — | — |
NCT03123445CT.gov Endostar First-line Treatment of Advanced NSCLC | — | Unknown | — | — | — |
NCT03169335CT.gov Efficacy and Safety of QL1101 and Avastin® Respectively Combined With Paclitaxel and Carboplatin in the First-line Treatment of Non-squamous Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT02864251CT.gov A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy | — | Completed | — | — | — |
NCT02998528CT.gov A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT03195569CT.gov To Predict Efficacy by Detecting Circulating Endothelial Cell Subsets and Blood Perfusion Parameters Changes in Vivo Tumor in Study of QL1101 and Avastin® in Patients With Non-squamous Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT03614065CT.gov Endostar Combine With Radiotherapy in Brain Metastasis of NSCLC | — | Unknown | — | — | — |
NCT03003962CT.gov Study of Durvalumab Alone or Chemotherapy for Patients With Advanced Non Small-Cell Lung Cancer (PEARL) | — | Active Not Recruiting | — | — | — |
NCT02944396CT.gov Study of Veliparib in Combination With Nivolumab and Platinum Doublet Chemotherapy in Participants With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT03062800CT.gov Study of Thalidomide in Treatment of Advanced Nsclc (Dream-003) | — | Unknown | — | — | — |
NCT02879097CT.gov Efficacy-Safety-Immunogenicity Study of CBT124&EU-sourced Avastin® in Stage 4 NSCLC | — | Unknown | — | — | — |
NCT02930954CT.gov Gefitinib Combined With Chemotherapy or Antiangiogensis in Patients With Bim Deletion or Low EGFR Mutation Abundance | — | Unknown | — | — | — |
NCT02922764CT.gov A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer | — | Completed | — | — | — |
NCT02897375CT.gov Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors | — | Completed | — | — | — |
NCT02579564CT.gov Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients | — | Unknown | — | — | — |
NCT02810457CT.gov Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT02862457CT.gov Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434) | — | Completed | — | — | — |
NCT02621398CT.gov Pembrolizumab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Stage II-IIIB Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT03850444CT.gov Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study | — | Completed | — | — | — |
NCT02754882CT.gov A Study Comparing SB8 and Avastin® in Patients With Advanced Non-squamous Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT02581943CT.gov Effect of Pembrolizumab With or Without Carboplatin and Paclitaxel on Immune Response in Patients With Recurrent or Stage IIIB-IV Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT02775435CT.gov A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407) | — | Completed | — | — | — |
NCT02716038CT.gov Neoadjuvant MPDL3280A, Nab-paclitaxel and Carboplatin (MAC) in NSCLC | — | Completed | — | — | — |
NCT02710396CT.gov Genetic Predictors of Benefit to Pembrolizumab | — | Terminated | — | — | — |
NCT02609776CT.gov Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT02657434CT.gov A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132) | — | Completed | — | — | — |
NCT02734524CT.gov A Clinical Research of NK Cell Infusion Combined With Chemotherapy in the Treatment of Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT02591615CT.gov Optimal Sequencing of Pembrolizumab (MK-3475) and Standard Platinum-based Chemotherapy in First-Line NSCLC | — | Completed | — | — | — |
NCT02662634CT.gov A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer | — | Withdrawn | — | — | — |
NCT03950674CT.gov Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study | — | Completed | — | — | — |
NCT02319889CT.gov Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma | — | Terminated | — | — | — |
NCT02525757CT.gov MPDL3280A With Chemoradiation for Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT02578680CT.gov Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189) | — | Completed | — | — | — |
NCT02492867CT.gov A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT02669719CT.gov Cellular Immunotherapy Synergize Chemotherapy in Patients With Stage IV NSCLC | — | Unknown | — | — | — |
NCT02631460CT.gov S1 vs.Pemetrexed Plus Carboplatin in Patients With EGFR Wild Type Stage IIIB or IV Nonsquamous NSCLC | — | Unknown | — | — | — |
NCT02574078CT.gov A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT02542293CT.gov Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE) | — | Active Not Recruiting | — | — | — |
NCT02567799CT.gov BIO 300 Non-Small Cell Lung Cancer Study | — | Completed | — | — | — |
NCT02576574CT.gov Avelumab in First-line NSCLC (JAVELIN Lung 100) | — | Completed | — | — | — |
NCT02392507CT.gov A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC | — | Completed | — | — | — |
NCT03780010CT.gov Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC | — | Completed | — | — | — |
NCT02477826CT.gov An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT02652234CT.gov Study of Endostar Subcutaneous Injection in NSCLC | — | Unknown | — | — | — |
NCT02453282CT.gov Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC) | — | Active Not Recruiting | — | — | — |
NCT02409342CT.gov A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110] | — | Completed | — | — | — |
NCT02419495CT.gov Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | — | Terminated | — | — | — |
NCT02382406CT.gov Carboplatin/Nab-Paclitaxel and Pembrolizumab in NSCLC | — | Terminated | — | — | — |
NCT02489903CT.gov RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT) | — | Completed | — | — | — |
NCT02337530CT.gov Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC | — | Completed | — | — | — |
NCT02409355CT.gov A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111) | — | Terminated | — | — | — |
NCT02412371CT.gov A Study Evaluating the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Adults With Stage III Non-Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT02309892CT.gov A Dose Escalation Study of L-DOS47 in Recurrent or Metastatic Non-Squamous NSCLC | — | Terminated | — | — | — |
NCT02367781CT.gov A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT02420314CT.gov Pharmacological Ascorbate for Lung Cancer | — | Completed | — | — | — |
NCT02366143CT.gov A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT02513355CT.gov Endostar Treatment of Advanced Non-small Cell Lung Cancer Multi-center Clinical Research | — | Unknown | — | — | — |
NCT01631357CT.gov Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer | — | Completed | — | — | — |
NCT02299765CT.gov Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC | — | Terminated | — | — | — |
NCT02407366CT.gov Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT02220894CT.gov Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042) | — | Completed | — | — | — |
NCT02279732CT.gov Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin | — | Completed | — | — | — |
NCT02264990CT.gov Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigator's Choice of Standard Chemotherapy in Adults Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) and Who Are Current or Former Smokers | — | Completed | — | — | — |
NCT02194738CT.gov Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) | — | Active Not Recruiting | — | — | — |
NCT02259621CT.gov Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC | — | Active Not Recruiting | — | — | — |
NCT02142738CT.gov Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024) | — | Completed | — | — | — |
NCT02083679CT.gov Sym004 in Subjects With Stage IV Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT01702714CT.gov A Study of RO5083945 in Combination With Cisplatin and Gemcitabine or Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer of Squamous Histology Who Have Not Received Prior Chemotherapy for The Metastatic Disease | — | Withdrawn | — | — | — |
NCT02148380CT.gov Combination of Chemotherapy and Gefitinib as First-line Treatment | — | Completed | — | — | — |
NCT02069158CT.gov Dose Finding Study Of PF-05212384 With Paclitaxel And Carboplatin In Patients With Advanced Solid Tumor | — | Completed | — | — | — |
NCT02095782CT.gov Chemotherapy and Erlotinib for Lung Cancer With Low Abundance Epidermal Growth Factor Receptor Mutation | — | Terminated | — | — | — |
NCT02087241CT.gov Ph II Trial of Carboplatin and Pemetrexed With or Without AZD1775 for Untreated Lung Cancer | — | Terminated | — | — | — |
NCT02039674CT.gov A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021) | — | Completed | — | — | — |
NCT01993810CT.gov Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer | — | Active Not Recruiting | — | — | — |
NCT02031601CT.gov Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer | — | Unknown | — | — | — |
NCT01982955CT.gov Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT) | — | Completed | — | — | — |
NCT01995188CT.gov A Study to Evaluate the Safety and Pharmacology of DNIB0600A in Participants With Platinum-Sensitive Ovarian Cancer or Non-Squamous Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT02001896CT.gov Erlotinib Intercalated With Chemotherapy Versus Erlotinib as First Line Treatment in Stage IIIB/IV NSCLC Patients With EGFR Mutation | — | Unknown | — | — | — |
NCT02009449CT.gov A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01966003CT.gov Efficacy and Safety Study of ABP 215 Compared With Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT01822496CT.gov Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT01249443CT.gov Paclitaxel and Carboplatin in Treating Patients With Metastatic or Recurrent Solid Tumors and HIV Infection | — | Terminated | — | — | — |
NCT01912625CT.gov Trametinib, Combination Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | — | Terminated | — | — | — |
NCT01980472CT.gov Chemotherapy Plus Bevacizumab in Elderly Non-small Cell Lung Cancer Patients | — | Unknown | — | — | — |
NCT02728492CT.gov Safety, Tolerability and Pharmacokinetics of Quisinostat, a Histone Deacetylase Inhibitor, in Combination With Chemotherapy | — | Completed | — | — | — |
NCT01828099CT.gov LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT01723800CT.gov PI3K Inhibitor BKM120, Carboplatin, and Pemetrexed Disodium in Treating Patients With Stage IV Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT01783197CT.gov Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC | — | Completed | — | — | — |
NCT01840579CT.gov Study of Pembrolizumab (MK-3475) Monotherapy in Advanced Solid Tumors and Pembrolizumab Combination Therapy in Advanced Non-small Cell Lung Cancer/ Extensive-disease Small Cell Lung Cancer (MK-3475-011/KEYNOTE-011) | — | Completed | — | — | — |
NCT01809210CT.gov Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT01836679CT.gov Chidamide in Combination With Carboplatin and Paclitaxel in Advanced Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT01836341CT.gov Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation | — | Withdrawn | — | — | — |
NCT01683682CT.gov An Dose Escalation Trial of Oral BIBF 1120 in Combination With Intravenous Carboplatin and Vinorelbine in Elderly Patients With Advanced Non-Small Cell Lung Cancer - Stage IV (VENUS-2) | — | Completed | — | — | — |
NCT01803282CT.gov Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Chemotherapy in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01820754CT.gov Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes (TILs) During / After Pre-Surgery Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT01860508CT.gov A Study of PC Sequential Pemetrexed Single Drug Maintenance Treatment for NSCLC and Related Predictive Biomarkers | — | Unknown | — | — | — |
NCT01872403CT.gov Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel/Carboplatin vs. Paclitaxel /Carboplatin in Stage Ⅱ B and IIIA Squamous Cell Carcinoma of the Lung | — | Unknown | — | — | — |
NCT01639001CT.gov A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients | — | Completed | — | — | — |
NCT01700400CT.gov Study of Everolimus, Pemetrexed, Carboplatin, and Bevacizumab to Treat Stage IV Lung Cancer | — | Completed | — | — | — |
NCT01666977CT.gov Phase 1b/2 Trial of AMG386 With Pemetrexed and Carboplatin in Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT02629848CT.gov Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT01494415CT.gov Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung Cancer | — | Unknown | — | — | — |
NCT02340208CT.gov A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47 | — | Completed | — | — | — |
NCT01519804CT.gov A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT01496742CT.gov A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT01560195CT.gov A Study of Pegylated rhG-CSF as Support to Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy Receiving Chemotherapy | — | Unknown | — | — | — |
NCT01593293CT.gov Pemetrexed With or Without Carboplatin for Elderly Non-squamous Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT01507428CT.gov Positron Emission Tomography and Computed Tomography in Guiding Radiation Therapy for Stage III Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT01560104CT.gov A Clinical Study Conducted in Multiple Centers Comparing Veliparib in Combination With Carboplatin and Paclitaxel Versus a Placebo in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT01493843CT.gov Safety and Efficacy of Carboplatin/Paclitaxel and Carboplatin/Paclitaxel/Bevacizumab With and Without Pictilisib in Previously Untreated Advanced or Recurrent Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT01649947CT.gov Modulation of Autophagy in Patients With Advanced/Recurrent Non-small Cell Lung Cancer - Phase II | — | Completed | — | — | — |
NCT01454102CT.gov Study of Nivolumab (BMS-936558) in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC) (CheckMate 012) | — | Completed | — | — | — |
NCT01478685CT.gov A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors | — | Completed | — | — | — |
NCT01531790CT.gov A Study of Continuous Endostar Intravenous Infusion Combined With Pemetrexed and Carboplatin in Advanced Non Small Cell Lung Cancer Patients | — | Completed | — | — | — |
NCT01533727CT.gov CIK Cell Transfusion Plus Chemotherapy as Adjuvant Therapy for Stage IB-IIIA Non-Small Cell Lung Cancer (NSCLC) | — | Withdrawn | — | — | — |
NCT01549093CT.gov Endostar Continued Pumping Into Vein Combining With Gemcitabine-Carboplatin to Treat Non-Small Cell Lung Cancer (NSCLC) | — | Unknown | — | — | — |
NCT01386385CT.gov Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | — | Active Not Recruiting | — | — | — |
NCT01404260CT.gov Intercalating and Maintenance Use of Iressa Versus Chemotherapy in Selected Advanced Non Small Cell Lung Cancer | — | Completed | — | — | — |
NCT01366131CT.gov Study Evaluating the Safety and Efficacy of MEGF0444A in Combination With Carboplatin, Paclitaxel and Bevacizumab in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer Who Have Not Received Prior Chemotherapy for Advanced Disease (NILE) | — | Completed | — | — | — |
NCT01393080CT.gov Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for the Advanced NSCLC Patients | — | Unknown | — | — | — |
NCT01244191CT.gov Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer | — | Terminated | — | — | — |
NCT01347424CT.gov Evaluating Endostatin Plus TC Regimen in Secondary Malignant Neoplasm of Liver Using Contrast Enhancement Ultrasonography | — | Unknown | — | — | — |
NCT01171170CT.gov Paclitaxel-Carboplatin-Bevacizumab +/- Nitroglycerin in Metastatic Non-Squamous-Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT01268059CT.gov A Study of Carboplatin and Paclitaxel With or Without MEDI-575 in Untreated, Advanced Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT01261299CT.gov Clinical Study of Microdosing Carboplatin in Lung or Bladder Cancer | — | Terminated | — | — | — |
NCT01310244CT.gov MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC | — | Completed | — | — | — |
NCT01413750CT.gov Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Advanced Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT01236716CT.gov Nab-Paclitaxel Treatment in Advanced Squamous Cell Carcinoma of Lung | — | Completed | — | — | — |
NCT01234038CT.gov Safety and Tolerability Study of ISIS EIF4E Rx in Combination With Carboplatin and Paclitaxel | — | Completed | — | — | — |
NCT01165216CT.gov Japanese Study of Ipilimumab Administered in Combination With Paclitaxel/Carboplatin in Patients With Nonsmall-cell Lung Cancer | — | Completed | — | — | — |
NCT01225302CT.gov A Study of Linifanib (ABT-869) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT01160744CT.gov A Study of Pemetrexed and Carboplatin/Cisplatin or Gemcitabine and Carboplatin/Cisplatin With or Without IMC-1121B in Participants Previously Untreated With Recurrent or Advanced Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT01212627CT.gov Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer | — | Terminated | — | — | — |
NCT01038752CT.gov Evaluation of Non-cytotoxic Suramin as a Chemosensitizer in Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT01160601CT.gov Study of Paclitaxel/Carboplatin With or Without Bavituximab in Previously Untreated Non Small-Cell Lung Cancer | — | Completed | — | — | — |
NCT01090830CT.gov Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT01199055CT.gov CS-7017 in Combination With Carboplatin/Paclitaxel in Subjects With Stage IIIb/IV Non-small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00955305CT.gov Paclitaxel, Carboplatin, and Bevacizumab With or Without Cixutumumab in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT01063283CT.gov Dose Escalation of Bevacizumab With Ambulatory Blood Pressure Monitoring in Patients With Advanced Non-squamous NSCLC | — | Completed | — | — | — |
NCT06585189CT.gov CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS4] | — | Completed | — | — | — |
NCT06607393CT.gov CARE Initiative: Real-world Emulation of the KEYNOTE-189 Trial [DS3] | — | Completed | — | — | — |
NCT01100931CT.gov A Phase I/II Study of Paclitaxel, Carboplatin and YM155 (Survivin Suppressor) in Subjects With Solid Tumors (Phase I) and Advanced Non-Small Cell Lung Carcinoma (Phase II) | — | Completed | — | — | — |
NCT00918203CT.gov A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT01000896CT.gov Study to Assess Safety and Tolerability of AZD0530 in Combination With Carboplatin and Paclitaxel | — | Withdrawn | — | — | — |
NCT01051934CT.gov A Phase I Trial of SS1 (dsFv) PE38 With Paclitaxel, Carboplatin, and Bevacizumab in Subjects With Unresectable Non-Small Cell Lung Adenocarcinoma | — | Completed | — | — | — |
NCT01192243CT.gov Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients | — | Unknown | — | — | — |
NCT01196234CT.gov Paclitaxel/Carboplatin (PC) Followed by Gefitinib Versus PC in Advanced Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT00970580CT.gov A Study of BIIB022 in Combination With Paclitaxel and Carboplatin in Subjects With Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT01158144CT.gov Concurrent Endostar, Paclitaxel/Carboplatin and Radiotherapy for Locally Advanced Non-small Cell Lung (RT0902) | — | Unknown | — | — | — |
NCT00974584CT.gov A Study of the Safety and Pharmacology Of PI3-Kinase Inhibitor GDC-0941 In Combination With Either Paclitaxel And Carboplatin (With or Without Bevacizumab) or Pemetrexed, Cisplatin, And Bevacizumab in Patients With Advanced Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00976456CT.gov Efficacy Study of Avastin® With Pemetrexed +/- Carboplatin to Treat Elderly Patients With Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT01028729CT.gov A Study of Endostar Combined With Chemotherapy Followed by Endostar Maintenance Therapy to Treat Advanced Non-small Cell Lung Cancer (NSCLC) | — | Unknown | — | — | — |
NCT00986674CT.gov Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00874848CT.gov Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT01209520CT.gov Residual Hypermethylation in Early Stage Non-Small Cell Lung Cancer (NSCLC) As Part of Adjuvant Therapy and Preventive Strategy | — | Completed | — | — | — |
NCT00850577CT.gov Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT00874107CT.gov Efficacy/Safety of Imprime PGG® Injection With Bevacizumab and Paclitaxel/Carboplatin in Patients With Untreated Advanced Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00991796CT.gov CS-1008 With Carboplatin/Paclitaxel in Chemotherapy naïve Subjects With Metastatic or Unresectable Non-small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00883675CT.gov Safety Study of Adjuvant Docetaxel-Carboplatin Treatment for Resected Lung Cancer | — | Completed | — | — | — |
NCT00883779CT.gov A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00800202CT.gov A Study of Avastin (Bevacizumab) in Patients With Non-Squamous Non-Small Cell Lung Cancer With Asymptomatic Untreated Brain Metastasis | — | Completed | — | — | — |
NCT00861627CT.gov Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation | — | Completed | — | — | — |
NCT00870870CT.gov A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before | — | Completed | — | — | — |
NCT00832819CT.gov E7080 in Combination With Carboplatin and Paclitaxel in Patients With Non-small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00599755CT.gov Phase I Imaging Study Evaluating Gem/Cis or Gem/Carbo for Participants With Non-Small Cell Lung Cancer (MK-0000-083 AM3) | — | Completed | — | — | — |
NCT00735696CT.gov A Study of Ramucirumab (IMC-1121B) With Paclitaxel and Carboplatin in Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT00820755CT.gov Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00828841CT.gov Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC | — | Completed | — | — | — |
NCT00723957CT.gov A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer | — | Completed | — | — | — |
NCT01687439CT.gov Effect of Endostar Combined With Chemotherapy and Radiotherapy on Blood Vessels and Microenvironment of Tumor for Non-small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00806286CT.gov Study of Carboplatin/Paclitaxel With or Without Investigational Drug (CS-7017) in Subjects With Metastatic Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT00754364CT.gov Mono Versus Polichemotherapy in Non Small Cell Lung Cancer (NSCLC) Elderly Patients | — | Terminated | — | — | — |
NCT00768131CT.gov A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel | — | Withdrawn | — | — | — |
NCT00702975CT.gov Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy | — | Completed | — | — | — |
NCT00741988CT.gov Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer | — | Completed | — | — | — |
NCT00756847CT.gov Safety Study of XL147 (SAR245408), in Combination With Paclitaxel and Carboplatin in Adults With Solid Tumors | — | Completed | — | — | — |
NCT00716534CT.gov Study of Carboplatin/Paclitaxel in Combination With ABT-869 in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00687817CT.gov Study of Bavituximab Plus Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00683904CT.gov Ixabepilone in Combination With Carboplatin in Patients With Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT00702572CT.gov Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT00600821CT.gov A Study Of AG-013736 (Axitinib) Or Bevacizumab (Avastin) In Combination With Paclitaxel And Carboplatin In Patients With Advanced Lung Cancer. | — | Completed | — | — | — |
NCT00662597CT.gov ASA404 or Placebo in Combination With Paclitaxel and Carboplatin as First-Line Treatment for Stage IIIb/IV Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT00687297CT.gov Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT00596830CT.gov Carboplatin And Paclitaxel With Or Without CP-751, 871 (An IGF-1R Inhibitor) For Advanced NSCLC Of Squamous, Large Cell And Adenosquamous Carcinoma Histology | — | Terminated | — | — | — |
NCT00903942CT.gov Abraxane and RT for Non-Small Cell Lung Cancer (NSCLC) | — | Withdrawn | — | — | — |
NCT00527735CT.gov Phase II Study for Previously Untreated Subjects With Non Small Cell Lung Cancer (NSCLC) or Small Cell Lung Cancer (SCLC) | — | Completed | — | — | — |
NCT00603538CT.gov Study of CP-751,871 in Combination With Carboplatin and Paclitaxel in Advanced Lung Cancer | — | Completed | — | — | — |
NCT02889666CT.gov A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer | — | Recruiting | — | — | — |
NCT00654758CT.gov A Phase 1b Study With Volociximab in Combination With Carboplatin and Paclitaxel in First-line, Advanced Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00621049CT.gov Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC | — | Completed | — | — | — |
NCT00540514CT.gov Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00647426CT.gov Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC | — | Completed | — | — | — |
NCT00614822CT.gov Carboplatin, Bevacizumab and Pemetrexed in Advanced Non Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00533429CT.gov Study of Pemetrexed + Carboplatin + Bevacizumab + Enzastaurin Versus Pemetrexed + Carboplatin + Bevacizumab + Placebo in Participants With Non-Small Cell Lung Cancer Who Have Not Been Previously Treated With Chemotherapy | — | Completed | — | — | — |
NCT00600587CT.gov Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00576225CT.gov CT-2103/Carboplatin vs Paclitaxel/Carboplatin for NSCLC in Women With Estradiol > 25 pg/mL | — | Withdrawn | — | — | — |
NCT00539331CT.gov Phase I/II Study of AZD2171 in Combination With Paclitaxel/Carboplatin in Japanese Non-Small Cell Lung Cancer Patients | — | Terminated | — | — | — |
NCT00535275CT.gov NSCLC Relapse Therapy After Surgery and Peri-operative Chemotherapy | — | Terminated | — | — | — |
NCT00558636CT.gov A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT00476216CT.gov Fondaparinux (Arixtra) With Chemotherapy for Advanced Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00786331CT.gov Pemetrexed +/- Carboplatin as Second Line Treatment in NSCLC | — | Unknown | — | — | — |
NCT00708812CT.gov Paclitaxel Plus Carboplatin With or Without Endostar in Patients With Advanced Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT00460317CT.gov MONET1-MOtesanib NSCLC Efficacy and Tolerability Study | — | Terminated | — | — | — |
NCT00480831CT.gov A Study of PRO95780 in Patients With Previously Untreated, Advanced-Stage Non-Small Cell Lung Cancer (APM4074g) | — | Completed | — | — | — |
NCT00481078CT.gov Vorinostat, Carboplatin, and Paclitaxel in Treating Patients With Advanced or Metastatic Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00473486CT.gov Study in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pemetrexed and Carboplatin Plus or Minus Sorafenib | — | Terminated | — | — | — |
NCT00473889CT.gov A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056) | — | Terminated | — | — | — |
NCT00400803CT.gov Carboplatin and Gemcitabine With Bevacizumab Every 2 Weeks for Stage IIIb/IV Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT00752115CT.gov Combination Chemotherapy With Sildenafil Plus Carboplatin and Paclitaxel in Patients With Advanced Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT00369070CT.gov A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC | — | Terminated | — | — | — |
NCT00583830CT.gov A Study of Mapatumumab in Combination With Paclitaxel and Carboplatin in Subjects With Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT00343291CT.gov A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC | — | Completed | — | — | — |
NCT00413283CT.gov Dose/ Schedule Finding Trial of Romiplostim for Chemotherapy-Induced Thrombocytopenia (CIT) in Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00347412CT.gov Study of NOV-002 in Combination With Chemotherapy to Treat Lung Cancer | — | Completed | — | — | — |
NCT01998919CT.gov A Study of Tarceva (Erlotinib) in Combination With Platinum Based Chemotherapy in Patients With Non-Small Cell Lung Cancer. | — | Completed | — | — | — |
NCT01069328CT.gov Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00508625CT.gov A Study of AMG 951 [rhApo2L/TRAIL] in Subjects With Previously Untreated Non-Small Cell Lung Cancer (NSCLC) Treated With Chemotherapy +/- Bevacizumab | — | Completed | — | — | — |
NCT00352690CT.gov A Phase II Study of Radiation Therapy, Paclitaxel Poliglumex, and Carboplatin in Stage III Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT00330044CT.gov Alimta, Carboplatin and Radiation Therapy for Non Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00308750CT.gov First Line Chemotherapy Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00322452CT.gov First Line IRESSA™ Versus Carboplatin/Paclitaxel in Asia | — | Completed | — | — | — |
NCT00300885CT.gov A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT01051362CT.gov Pegylated Liposomal Doxorubicin and Carboplatin as First Line Treatment for Patients With Advanced Non-small Cell Lung Cancer | — | Unknown | — | — | — |
NCT00294762CT.gov Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC | — | Completed | — | — | — |
NCT00313768CT.gov Randomized Ph 2 Trial Of Paclitaxel/Carboplatin /Bevacizumab + PF-3512676 And P/C/B Alone In Advanced Nonsquamous NSCLC | — | Terminated | — | — | — |
NCT00243867CT.gov Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer | — | Completed | — | — | — |
NCT00254891CT.gov Trial of Paclitaxel/Carboplatin + PF-3512676 vs Paclitaxel/Carboplatin Alone in Patients With Advanced Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT00152477CT.gov A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer | — | Completed | — | — | — |
NCT00240097CT.gov Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC) | — | Completed | — | — | — |
NCT02182232CT.gov A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung Cancer | — | Completed | — | — | — |
NCT00274443CT.gov An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin | — | Completed | — | — | — |
NCT00147537CT.gov Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer | — | Completed | — | — | — |
NCT00094861CT.gov Study to Evaluate Palifermin in the Reduction of Dysphagia in Patients With Locally Advanced Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00094835CT.gov Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00112294CT.gov Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00097227CT.gov Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00097214CT.gov Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00264498CT.gov Phase II Iressa & Carbo/Gem in NSCLC | — | Completed | — | — | — |
NCT00735878CT.gov Pharmacokinetic & Pharmacodynamic Study of ABT-751 With Carboplatin in Patients With Advanced Lung Cancer | — | Terminated | — | — | — |
NCT00832494CT.gov Phase II Study of DMXAA (ASA404) in Combination With Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00088556CT.gov Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00259675CT.gov Alternating Cycles of Carboplatin/Gemcitabine and Carboplatin/Taxol for Advanced Stage NSCLC | — | Completed | — | — | — |
NCT00086268CT.gov Non-small Cell Lung Cancer Study US75 (Z-PACT) | — | Completed | — | — | — |
NCT00088088CT.gov STA-4783 in Combination With Paclitaxel and Carboplatin for the Treatment of Chemotherapy Naive Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00087802CT.gov Gemcitabine/Oxaliplatin (GEMOX) vs Carboplatin/Paclitaxel (CP) in Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00071188CT.gov ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00085839CT.gov Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2 | — | Completed | — | — | — |
NCT00132665CT.gov Trial to Evaluate Radiotherapy With or Without CBDCA in Elderly Patients With Non-Small Cell Lung Cancer (JCOG0301) | — | Completed | — | — | — |
NCT00061646CT.gov Safety and Effectiveness of ABT-510 Plus Combination Chemotherapy in Subjects With Non-Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT00463515CT.gov Evaluation of Carboplatin Plus Gemcitabine Followed by Concomitant Chemoradiation for Non-resectable Stage III NSCLC | — | Completed | — | — | — |
NCT00198367CT.gov Three Modalities of Treatment in Operable and Resectable Stage IIIA (T1-3, N2) Non-Small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT00174356CT.gov PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients | — | Completed | — | — | — |
NCT00252798CT.gov ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00148395CT.gov Randomized Phase III-Study in Stage IIIb and IV Non-Small-Cell Lung Cancer. Sequential Single-Agent vs. Double-Agent vs. Triple-Agent Therapy. | — | Completed | — | — | — |
NCT00042679CT.gov A Phase 2 Trial of Antisense Nucleotide to PKC-Alpha (LY900003, ISIS 3521) Plus Gemcitabine and Carboplatin in Patients With Advanced, Previously Untreated Non-Small Cell Lung Cancer. | — | Completed | — | — | — |
NCT00042302CT.gov A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Phase III Study of Tariquidar + Paclitaxel/Carboplatin as First-Line Therapy in Non-Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT00040794CT.gov Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00050960CT.gov Evaluation of Efficacy, Safety and Tolerability of Targretin Capsules in Patients With Advanced or Metastatic Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT00051493CT.gov ALIMTA Plus Carboplatin as Front-Line Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer: A Phase 2 Clinical Trial. | — | Completed | — | — | — |
NCT00034346CT.gov ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT01652820CT.gov Chemotherapy/Radiotherapy Versus Concomitant Chemotherapy Followed by Radiotherapy in Stage IIIB Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT00437749CT.gov A Study of CBT-1 and Paclitaxel With Carboplatin in Patients With Advanced Inoperable Non-small Cell Lung Cancer | — | Terminated | — | — | — |
NCT01004731CT.gov Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer | — | Completed | — | — | — |
NCT00198354CT.gov Stage I/II NSCLC Perioperative Chemotherapy | — | Completed | — | — | — |
NCT00034541CT.gov Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00006929CT.gov Suramin, Paclitaxel, and Carboplatin in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT00212043CT.gov Phase I/II Trial of Infusional Gemcitabine in Combination With Carboplatin in Chemonaive Non-small Cell Carcinoma | — | Completed | — | — | — |
NCT00005838CT.gov Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery | — | Completed | — | — | — |
NCT00005065CT.gov Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer | — | Completed | — | — | — |
NCT00913705CT.gov Neoadjuvant or Adjuvant Chemotherapy in Patients With Operable Non-small-cell Lung Cancer | — | Completed | — | — | — |
NCT00004074CT.gov Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu | — | Completed | — | — | — |
NCT00265694CT.gov Random Trial for Elderly Patients With NSCLC | — | Unknown | — | — | — |
NCT00049790CT.gov Safety and Efficacy Study of rhAngiostatin Administered in Combination With Paclitaxel and Carboplatin to Patients With Non-Small-Cell Lung Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Carboplatin (this asset) | Jonsson Comprehensive Cancer Center | Approved | BB · 69 |
| Necitumumab | Jonsson Comprehensive Cancer Center | P3 | BBB |
| Glumetinib | Shanghai JMT-Bio Inc. | P3 | BBB |
| Veliparib | AbbVie | P3 | BBB |
| d-0316 | Betta Pharmaceuticals Co., Ltd. | P2/3 | BBB |
| Icotinib | The First Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Zoledronate | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P4 | BBB |
| Onartuzumab | Hoffmann-La Roche | P3 | BBB |
| Avitinib | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | P3 | BBB |
+42 more in the Non-Small Cell Lung Carcinoma cohort
Other indications for Carboplatin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Lung Large Cell Carcinoma | — | P4 | A · 80 |
| Primary Peritoneal Carcinoma | — | P3 | BBB · 76 |
| Non-Small Cell Squamous Lung Carcinoma | — | P3 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Carboplatin in Non-Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 11, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/carboplatin-non-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →